Ababax Health

Ababax Health is a clinical-stage biotechnology company focused on developing innovative small molecule therapeutics for the treatment of cancer. The company leverages synthetic lethality and DNA damage response (DDR) pathways to target specific vulnerabilities in tumor cells. Its lead candidate, ABX-002, is a potent and selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1), currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. Ababax specifically targets cancers with homologous recombination deficiency (HRD), aiming to provide new treatment options for patients who have become resistant to PARP inhibitors. Headquartered in San Diego, the company is led by an experienced management team and backed by top-tier life science investors like OrbiMed.